Overview

Pharmacokinetics and Safety in Healthy Volunteers

Status:
Completed
Trial end date:
2014-06-20
Target enrollment:
Participant gender:
Summary
Investigate the pharmacokinetics, safety and tolerability of BI695501 and to establish pharmacokinetic similarity of BI 695501 to adalimumab.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Adalimumab